2018-present: Part-time Senior Researcher, SUNUM Nanotechnology Research and Application Center.
2020-present: Research Team Leader, KUTTAM Research Center for Translational Medicine, Koç University Hospital.
2020-present: Tenured Professor and Research Team Leader, Koç University School of Medicine.
2018-present: International Council Member and Affiliate Member, Autophagy, Inflammation: and Metabolism (AIM) Center of Biomedical Research Excellence, University of New Mexico Health Sciences Center, USA.
2006-2020: Professor, Sabanci University, Istanbul.
2017-2019: Advisory Board Member, TÜSEB (Turkish NIH) Biotechnology Institute
2016-2020: Founding Board Member, EFSUN Center of Excellence for Nano Diagnostics.
2001-2006: Postdoctoral Fellow, Weizmann Institute of Science, Rehovot (Adi Kimchi Lab).
1997-2001: PhD Student Researcher, Pasteur Institute and Necker Children’s Hospital IRNEM, Paris (Christian Brechot Lab).
1996-1997: MSc Student Researcher, Ecole Polytechnique, Paris (Andrea Parmeggiani Lab).
Disease markers and drug target discovery,
Targeted drug delivery,
Nanotechnology for disease diagnosis and follow-up,
Unal O, Akkoc Y, Kocak M, Nalbat E, Dogan-Ekici AI, Yagci Acar H, Gozuacik Dx. Treatment of breast cancer with autophagy inhibitory microRNAs carried by AGO2-conjugated nanoparticles. J Nanobiotechnology. 2020 Apr 28;18(1):65. doi: 10.1186/s12951-020-00615-4 https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-020-00615-4
Demir-Duman F, Akkoc Y, Demirci G, Bavili N, Kiraz,A, Gozuacik Dx, Yagci Acar Hx. Bypassing pro-survival and resistance mechanisms of autophagy in EGFR-positive lung cancer cells by targeted delivery of 5FU using theranostic Ag2S quantum dots. Journal of Materials Chemistry B, 2019 Dec 14;7(46):7363-7376 https://pubs.rsc.org/en/content/articlelanding/2019/tb/c9tb01602c#!divAbstract
Yar Y, Khodadust R, Akkoc Y, Utkur M, Saritas EU, Gozuacik D, Yagci Acar Hx. Development of Tailored SPION-PNIPAM Nanoparticles by ATRP for Dually Responsive Doxorubicin Delivery and MR Imaging. Journal of Materials Chemistry B, 2018, 6, 289 – 300. (Impact factor: 4.54. Times cited: 2) https://pubs.rsc.org/en/content/articlelanding/2017/tb/c7tb00646b#!divAbstract
Demir F, Hocaoglu I,Ozturk DG, Gozuacik D, Kiraz A, Yagci Acar Hx. Highly Luminescent and Cytocompatible Cationic Ag2S NIR-emitting Quantum Dots for Optical Imaging and Gene Transfection. Nanoscale, 2015, DOI: 10.1039/C5NR00189G. (Impact factor: 7.36. Times cited: 26) https://pubs.rsc.org/en/content/articlelanding/2014/nr/c5nr00189g#!divAbstract
Gozuacik Dx, Yagci-Acar HF, Akkoc Y, Kosar A, Dogan-Ekici AI, Ekici S. Anticancer use of nanoparticles as nucleic acid carriers. Journal of Biomedical Nanotechnology, 2014, September; 10(9): 1751-1783. (Impact factor: 5. Times cited: 18) https://www.ingentaconnect.com/content/asp/jbn/2014/00000010/00000009/art00006
Gozuacik D, Kutlu O, Akkoc Y, Akkiz H. IL as a novel biomarker and drug target in fatal liver cancer. WIPO-Patent Cooperation Treaty. Application Number: PCT/TR2019/051107. December 18, 2019. Pending.
Gozuacik D, Kutlu O, Kocaturk NM, Kilislioglu A, Karakus S, Kutlu M, Ilgar M, Ben Taleb AM, Tan E. Nano formulations comprizing Ceranib-2. WIPO-Patent Cooperation Treaty. Application Number: PCT/TR2019/050247. April 16, 2019. Pending.
Akgonul S, Zuvin M, Sevgen MI, Kosar A, Gozuacik D; Kutlu O, Yagci-Acar H. Rotary Magnetic Actuation System. WIPO-Patent Cooperation Treaty. Application Number: PCT/TR2019/050115. February 20, 2019. Pending.
Gozuacik D, Ozturk DG, Kocak M. Stress-Regulated MiRNAs As Novel Cancer Biomarkers. WIPO-Patent Cooperation Treaty. Application Number: PCT/TR2019/050004. January 2, 2018. Pending.
Yagci-Acar H, Gozuacik D, Kosar A, Unal O, Kocak M, Akkoc Y, Zuvin M. Therapeutic nanoparticles containing a protein for microRNA delivery and compositions and methods using same. WIPO-Patent Cooperation Treaty. Application Number: PCT/TR2018/050094. March 10, 2018. Pending.
Kosar A, Gozuacik D, Sadaghiani AH, Motazakker A, Akkoc Y. Heat exchanger with enhanced heat transfer surfaces. Turkish Patent Institute. Application Number: 17T-10468. April 14, 2017. Pending.
Gozuacik D. Usage of FC for cancer diagnosis and treatment. European Patent Office Patent Application Number: EP3067422. March 13, 2013. Pending.
Cho YK, Bathany C, Kim JY, Gozuacik D. Device and method for single cell screening-based on inter-cellular communication. WIPO-Patent Cooperation Treaty. Patent Application Number: WO2016099207. June 23, 2016. Pending. USA Patent Office. Patent Number: 10385306. August 20, 2019. Approved.
Gozuacik D and Korkmaz G (PhD Student). Use of miRNAs for the diagnosis, propylaxis, treatment and follow-up of diseases involving macroautophagy abnormalities. European Patent Office Patent Number: EP10777121.4. April 05, 2012-2015. Approved.
2010-today, Board of Directors Member, International Cell Death Society
(ICDS) (Based in New York) (www.celldeath-apoptosis.org)
2016-today, Founding Member, Turkish Cell Death Research Society (HOAD).
2011-today, Founding Member, Turkish Molecular Biology Society (MBD).
2016-2017, Board Member, Turkish Cell Death Research Society (HOAD).
2011-2013, Board Member, Turkish Molecular Biology Society (MBD).
2015: Elginkan Foundation Technology Award (together with the SUTAB medical device team)
2014: TGC Sedat Simavi Health Sciences Award
2014: IKU Prof. Onder Oztunali Science Award
2008: Turkish Academy of Sciences, Successful Young Scientist Award (TÜBA-GEBİP).
2006: European Molecular Biology Organization, Strategical Development and Installation Award (EMBO-SDIG).
2006: Selected by Roche Pharmaceuticals among the “Bioscience Leaders of the Next Decade”.